<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9803">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01744405</url>
  </required_header>
  <id_info>
    <org_study_id>LACT-NIFURTIMOX</org_study_id>
    <nct_id>NCT01744405</nct_id>
  </id_info>
  <brief_title>Study Of Nifurtimox Transfer Into Breastmilk In Lactating Women With Chagas Disease</brief_title>
  <acronym>LACTNFX</acronym>
  <official_title>Study Of Nifurtimox Transfer Into Breastmilk In Lactating Women With Chagas Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Niños R. Gutierrez de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Niños R. Gutierrez de Buenos Aires</source>
  <oversight_info>
    <authority>Argentina: Human Research Bioethics Committee</authority>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to study the transfer of nifurtimox into breastmilk  of lactating
      women who receive the drug for the treatment of Chagas disease.

      Breastmilk and blood samples will be obtained from these patients at pre-specified times
      after they take the clinically indicated medication, and the concentrations in both matrices
      will be compared to estimate degree of transfer. Estimation of nifurtimox transfer into
      breastmilk will allow the evaluation of potential degree of exposure of infants breastfed by
      these women to nifurtimox. This study will help clarify safety of continuing breastfeeding
      while receiving treatment with nifurtimox for Chagas disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Nifurtimox concentration in breastmilk and in plasma</measure>
    <time_frame>at randomly selected, pre-specified, time points during the 30 days of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Randomly obtained breastmilk samples will be obtained to both evaluate the breastmilk / plasma concentration ratio of the drug, and to develop a population pharmacokinetics model of drug transfer into breastmilk, if possible.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse drug reactions in women treated with nifurtimox during lactation</measure>
    <time_frame>throughout the 30 days of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Women receiving treatment with nifurtimox while lactating, enrolled in the study will be followed according to current clinical guidelines, and monitored during the 30 days of treatment (as per Chagas disease treatment guidelines), and monthly for 3 months after treatment completion.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Chagas Disease</condition>
  <condition>Lactation</condition>
  <arm_group>
    <arm_group_label>Lactating Women with Chagas disease</arm_group_label>
    <description>Women with Chagas disease who fulfill clinical criteria for treatment with nifurtimox, and who are also lactating</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      breastmilk; plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Population of young women with Chagas disease referred to our center for evaluation and
        treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lactating women with Chagas disease, not treated before

          -  Use of contraception

        Exclusion Criteria:

          -  History of allergy to nifurtimox or its excipients

          -  Pregnancy

          -  Significant heart involvement (due to Chagas disease)

          -  Significant systemic diseases that could affect the interpretation of the results in
             the opinion of the principal investigator
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Facundo Garcia Bournissen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Buenos Aires Children´s Hospital Ricardo Gutierrez ; CONICET</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jaime Altcheh, MD</last_name>
    <phone>+5411-49624122</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Facundo Garcia Bournissen, MD PhD</last_name>
    <phone>+5411-49624122</phone>
    <email>facugb1@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Parasitology and Chagas Service, Buenos Aires Children´s Hospital Ricardo Gutierrez</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jaime Altcheh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Facundo Garcia Bournissen, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samanta Moroni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillermo Moscatelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 5, 2012</lastchanged_date>
  <firstreceived_date>December 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Niños R. Gutierrez de Buenos Aires</investigator_affiliation>
    <investigator_full_name>Facundo Garcia-Bournissen</investigator_full_name>
    <investigator_title>Associate Resesarcher</investigator_title>
  </responsible_party>
  <keyword>Chagas disease</keyword>
  <keyword>lactation</keyword>
  <keyword>breastmilk</keyword>
  <keyword>postpartum period</keyword>
  <keyword>infants</keyword>
  <keyword>pediatric clinical pharmacology</keyword>
  <keyword>developmental clinical pharmacology</keyword>
  <keyword>parasitology</keyword>
  <keyword>trypanosoma cruzi</keyword>
  <keyword>nifurtimox</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chagas Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nifurtimox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
